Statements (18)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:chemical_compound
|
| gptkbp:alternativeName |
TNP-165
TNP165A |
| gptkbp:CASNumber |
gptkb:170729-80-3
|
| gptkbp:chemicalFormula |
C17H18N2O2S
|
| gptkbp:clinicalTrialPhase |
Phase II
|
| gptkbp:developedBy |
gptkb:Taisho_Pharmaceutical
|
| gptkbp:drugClass |
antidepressant
|
| gptkbp:has_therapeutic_use |
gptkb:major_depressive_disorder
|
| https://www.w3.org/2000/01/rdf-schema#label |
TNP-165A
|
| gptkbp:IUPACName |
(2S)-2-(4-methoxyphenyl)-2-[(4-methylphenyl)sulfanyl]acetamide
|
| gptkbp:mechanismOfAction |
NMDA receptor antagonist
|
| gptkbp:molecularWeight |
314.4 g/mol
|
| gptkbp:PubChem_CID |
CHEMBL2105702
9843482 |
| gptkbp:routeOfAdministration |
oral
|
| gptkbp:bfsParent |
gptkb:T-72B
|
| gptkbp:bfsLayer |
6
|